skip to content
Primary navigation


Drug - Inlyta

June 2012

Therapeutic area - Oral Oncology

Approval criteria

  • Patient has diagnosis of renal cell carcinoma AND
  • Patient has tried and failed 1 of the following drugs: sorafenib, sunitinib, temsirolimus, everolimus, bevacizumab, or pazopanib

Quantity limit

Quantity Limit = 136 tablets

Background information

INLYTA is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. The 2012 NCCN guidelines for patient with clear cell histology recommend axitinib in patients who have failed at least one prior systemic therapy, oral or injectable.

Inlyta is subject to quantity level limits and prior authorization.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top